Age-related macular degeneration（AMD） - Medical Tourism & Treatment Guide in China

Age-related macular degeneration (AMD) is a progressive, degenerative retinal disorder primarily affecting the macula—the central portion of the retina responsible for high-acuity and color vision. It is the leading cause of irreversible central vision loss in adults over 50 years old worldwide. AMD manifests in two primary forms: dry (atrophic), characterized by drusen accumulation and gradual photoreceptor atrophy, and wet (neovascular), marked by abnormal choroidal neovascularization, leakage, and rapid vision deterioration. Risk factors include advancing age, genetic predisposition (e.g., variants in CFH and ARMS2 genes), smoking, hypertension, and prolonged UV exposure. Diagnosis relies on comprehensive ophthalmic evaluation—including best-corrected visual acuity testing, dilated fundus examination, spectral-domain optical coherence tomography (SD-OCT), and fluorescein or indocyanine green angiography. While dry AMD lacks disease-modifying therapy beyond AREDS2-formula supplementation and lifestyle modification, wet AMD is effectively managed with intravitreal anti-VEGF agents (e.g., ranibizumab, aflibercept, conbercept), often requiring sustained treatment to preserve vision.

China offers compelling advantages for AMD management: its ophthalmology centers—many affiliated with top-tier universities—boast internationally trained retinal specialists with extensive experience in complex anti-VEGF protocols and emerging therapies such as brolucizumab and faricimab. State-of-the-art imaging platforms (e.g., OCT-angiography, adaptive optics scanning laser ophthalmoscopy) enable precise disease staging and treatment monitoring. Clinical outcomes align closely with global benchmarks: multi-center studies report ≥85% of wet AMD patients maintain stable or improved vision after one year of standardized anti-VEGF regimens. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising regulatory standards, as all approved biologics undergo rigorous review by China’s National Medical Products Administration (NMPA). As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting JCI-accredited hospitals, coordinating appointments with certified retinal specialists, providing transparent, all-inclusive pricing (covering diagnostics, injections, follow-ups, and translation), and offering end-to-end support—from visa assistance and accommodation to post-treatment telemedicine consultations.